Zack Ajzenman just had to take Syneron Medical Ltd. up on an offer to try its fat-reduction machine, the UltraShape.
It wasn’t so much about his weight. At 175 pounds, Ajzenman, an equity analyst at Griffin Securities Inc., considers himself a fit enough guy. His issue is that he’s got a buy recommendation on Syneron and the stock is plunging. If the fat-busting ultrasound machine is going to fuel the kind of revenue rebound that Syneron envisions, and turn around the stock, the treatment truly has to be painless as the company claims.